spacer
home > ebr > summer 2018 > driving discovery
PUBLICATIONS
European Biopharmaceutical Review

Driving Discovery

EBR: What are the benefits of mass spectrometry (MS) as an analytical method?

Simon Cubbon: MS, from its early beginnings through to its current use, has seen an ever-increasing adoption; this is because of the large amounts of information, resulting in quality and, therefore, confidence that this technique can provide, ultimately, safeguarding end-users.

Additionally, both high- and low-resolution systems are becoming increasingly simpler to use; this, combined with the intricacy of products being brought to market (eg protein-based therapeutics, such as monoclonal antibodies or antibodydrug conjugates), requires techniques that can provide the necessary structural insights needed to fully characterise and understand these complexities.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Simon Cubbon works as a pharma and biopharmaceutical Vertical Marketing Manager at Thermo Fisher Scientific. He has worked within the analytical instruments industry for over 10 years, holding a variety of positions from applications scientist through to informatics product management. Simon studied for his PhD at the University of York, UK, where he was interested in using LC-MS to study the metabolic profile of long bone fractures.
spacer
Dr Simon Cubbon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.
More info >>

White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

 
Industry Events

Pharmaceutical Packaging and Device Labelling Europe

11-12 September 2018, Munich, Germany

Relaunching the event after a three year hiatus, Pharma Packaging and Labelling Europe is back to deliver key, actionable insight on the very latest regulatory requirements, technological innovations, strategic developments, and how to implement them into your packaging and labelling chain with both maximum efficiency and minimal cost. The conference is packed with thought provoking innovative discussions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement